ADMA ADMA Biologics Inc
Company Analysis
Latest News
🟢 ADMA Biologics is trading 10% up today after stronger profitability despite revenue miss
ADMA Biologics is trading $10.19 (+9.99%) after second-quarter earnings on August 5, 2026, showed stronger profitability despite a slight revenue miss. •...
ADMA Biologics reports a second quarter EPS beat despite a slight revenue miss, driven by 24% ASCENIV growth.
ADMA Biologics reported second quarter 2026 revenue of $124.4 million, up 2% year-over-year but slightly missing analyst estimates of $125.34 million. The...
🟢 ADMA Biologics is trading 4.2% up today ahead of Q2 earnings and biotech sector strength
ADMA Biologics is trading 4.2% up at $9.29 as traders position ahead of its second-quarter 2026 earnings release scheduled for August 05, 2026. • The stock is...
ADMA Biologics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect ADMA Biologics to report Q2 2026 revenue of $125.34 million and EPS of $0.16, as the stock trades near $8.46 against a median analyst price...
🟢 ADMA Biologics is trading 4.1% up today despite no clear company-specific news catalyst
ADMA Biologics is trading at $9.02 (4.1% up) in after-hours trading despite a lack of fresh, company-specific headlines such as earnings, FDA decisions, or...
🔴 ADMA Biologics is trading 4.4% down today with no clear catalyst identified
ADMA Biologics is trading at $8.40 (4.4% down) in after-hours trading with no clear catalyst identified for the move. • The decline follows a recent multi-day...
ADMA Biologics faces fraud lawsuit, following alleged channel stuffing and stock crash
Multiple law firms filed a securities fraud class-action lawsuit against ADMA Biologics, Inc. The complaint alleges the company issued misleading statements...
ADMA Biologics hit with fraud lawsuit, alleging revenue inflation and hidden deals
Multiple law firms filed a securities fraud class-action lawsuit against ADMA Biologics, Inc. and its executives. The complaint alleges the company made false...
🔴 ADMA is trading 5% down today as class-action lawsuit notices resurface
ADMA is trading 5.09% down at $8.30 after fresh class-action lawsuit notices resurfaced against the company. • Investor law firm coverage on June 29...
🟢 ADMA Biologics Inc is trading 80% up today after a sharp after-hours spike on no immediate news
ADMA Biologics Inc is trading 80% up at $15.18 after a sharp after-hours spike with no immediate public catalyst. • The stock surged from its regular-session...
ADMA Biologics sued for fraud, alleging channel stuffing and revenue inflation
Multiple law firms filed a class-action lawsuit against ADMA Biologics, Inc. and its executives. The suit alleges the company committed securities fraud...
Raymond James Slaps a $21 Target on ADMA Biologics — But Can a Beaten-Down Plasma Maker Really More Than Double?
Shares of ADMA Biologics surged 7.6% to $8.74 on June 10 after Raymond James initiated coverage with an Outperform rating and a $21 price target — implying...
🟢 ADMA Biologics Inc is trading 7.6% up today after Raymond James initiates coverage with a $21 price target
ADMA Biologics Inc is trading 7.6% up today at $8.74 following a bullish initiation from Raymond James. • Raymond James issued an Outperform rating and a $21...
🟢 ADMA Biologics surges 6.6% after Raymond James initiates with 'Outperform' rating
ADMA Biologics Inc. is trading 6.6% up at $8.66 after Raymond James initiated coverage on the stock with an 'Outperform' rating and a $21 price target. • The...
🔴 ADMA Biologics slides 5.9% as securities fraud investigations mount
ADMA Biologics Inc. is trading 5.9% down at $7.50 in pre-market trading as the stock continues to face pressure from recent negative developments. • The...
🟢 ADMA Biologics Inc is trading 10% up today on momentum and speculative interest
ADMA Biologics Inc is trading 10% up at $8.80 in pre-market, extending a multi-day uptrend that started in late May. • The move appears driven by momentum and...
🟢 ADMA Biologics Inc is trading 10% up today on momentum with no clear catalyst
ADMA Biologics Inc is trading 10% up at $8.80 in pre-market, driven by momentum and speculative interest as no fresh company-specific news has been reported...
🔴 ADMA Biologics Inc is trading 5.3% down today amid renewed focus on short-seller claims and growth-quality concerns
ADMA Biologics Inc is trading 5.3% down now at $7.48 amid renewed focus on earlier short-seller claims and growth-quality concerns. • Investors are...
ADMA Biologics Wins FDA Approval for ASCENIV, Expanding Use to Children 2+
ADMA Biologics received FDA approval to expand the label for its drug ASCENIV. The therapy treats primary humoral immunodeficiency (PI). The approval expands...
Law Firm Announces Investigation into ADMA Biologics for Potentially Misleading Investors
The law firm Bleichmar Fonti & Auld LLP announced it is investigating ADMA Biologics for potential violations of federal securities laws. The investigation...